Artiva nabs $120M for NK cell therapies

By The Science Advisory Board staff writers

February 26, 2021 -- Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research and development activities.

The company's cell therapies use the innate antitumor biology and safety features of NK cells. They target cancer through the use of chimeric antigen receptors (CARs) or antibody-dependent cellular cytotoxicity (ADCC) enhancement through therapeutic antibody or innate cell engager combination therapy.

The company's pipeline includes the following:

  • AB-101, an ADCC enhancer NK cell therapy for use in combination with monoclonal antibodies or innate cell engagers
  • AB-201, a novel human epidermal growth factor receptor 2 (HER2)-specific CAR-NK cell therapy for treating HER2+ solid tumors
  • AB-202, a CD19-specific CAR-NK cell therapy for treating B-cell malignancies

The NK cell platform incorporates cell expansion, activation, and engineering technology developed by corporate partner GC LabCell, a member of the GC family of companies.

Artiva's manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity, Artiva said.

The series B financing round was led by Venrock Healthcare Capital Partners.

Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...
Artiva, Merck to develop CAR NK cell therapies
Artiva Biotherapeutics and Merck have signed an agreement to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics for solid tumors.
Cytovia licenses CAR NK tech to NCI
Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its...
$105M raised for Senti Bio to develop CAR-NK therapies
Leaps by Bayer, the investment arm of Bayer AG, and Senti Biosciences (Senti Bio) have announced a $105 million series B financing round to develop...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter